On Friday, U.S. Rep. Martha Roby (R-Montgomery) released a letter that was signed by her and 117 of her colleagues sent to Dr. Norman Sharpless, the acting commissioner of the Food and Drug Administration (FDA).
According to a release that accompanied the letter, it urged Sharpless to crack down on Aid Access and Rablon, two foreign companies that have been known to distribute Mifeprex, a chemical abortion drug. That drug is offered mail-order to U.S. customers, which is an apparent violation of the FDA’s safety protocols.
During an appearance on WVNN’s “The Jeff Poor Show” on Thursday, Roby elaborated on the letter regarding the abortion drug, which she argued posed a “significant health risk” to women and unborn children.
“[I]’m currently leading a letter,” she said. “It’s signed by 117 of my House colleagues that will be sent to Dr. Norman Sharpless, the acting commissioner of the Food and Drug Administration. We are urging him in this letter to crack down on foreign companies that have been known to distribute a chemical abortion drug by mail order to U.S. customers. This practice is already illegal. It violates the FDA’s existing safety protocols. But it is still happening. And so, the drug in question is approved by the FDA, but it’s not available in retail pharmacies, and it’s not legally available on the internet. But certain abortion by mail providers primarily based in Europe – they’ve widened their consumer base to include the U.S.”
“These companies provide remote consultations to U.S. residents,” she continued. “They send this abortion drug to be filled in India. Then they send it by mail to customers in the United States. So, I think it goes without saying that this practice poses a significant health risk to women and their unborn children. And again, the point of the letter is FDA must take decisive action against these companies immediately.”
@Jeff_Poor is a graduate of Auburn University, the editor of Breitbart TV and host of “The Jeff Poor Show” from 2-5 p.m. on WVNN in Huntsville.
Don’t miss out! Subscribe today to have Alabama’s leading headlines delivered to your inbox.